Enhancing Targeted Therapy in Hepatocellular Carcinoma through a pH-Responsive Delivery System: Folic Acid-Modified Polydopamine-Paclitaxel-Loaded Poly(3-hydroxybutyrate- co -3-hydroxyvalerate) Nanoparticles
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.3c00710 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Mingfang Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological and Chemical Engineering, Zhejiang University of Science and Technology, Hangzhou 310023, Zhejiang, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Nanoparticles, Polyhydroxybutyrates. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Zhejiang University of Science and Technology.
Abstract (Originalsprache)
Currently, there is an inherent contradiction between the multifunctionality and excellent biocompatibility of anticancer drug nanocarriers, which limits their application. Therefore, to overcome this limitation, we aimed to develop a biocompatible drug delivery system for the treatment of hepatocellular carcinoma (HCC). In this study, we employed poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) as the fundamental framework of the nanocarrier and utilized the emulsion solvent evaporation method to fabricate nanoparticles loaded with paclitaxel (PTX), known as PTX-PHBV NPs. To enhance the tumor-targeting capability, a dopamine self-polymerization strategy was employed to form a pH-sensitive coating on the surface of the nanoparticles. Then, folic acid (FA)-targeting HCC was conjugated to the nanoparticles with a polydopamine (PDA) coating by using the Michael addition reaction, resulting in the formation of HCC-targeted nanoparticles (PTX-PHBV@PDA-FA NPs). The PTX-PHBV@PDA-FA NPs were characterized and analyzed by using dynamic light scattering, scanning electron microscopy, fourier-transform infrared spectroscopy, X-ray diffraction, differential scanning calorimetry, and thermogravimetric analysis. Encouragingly, PTX-PHBV@PDA-FA NPs exhibited remarkable anticancer efficacy in an HCC xenograft mouse model. Furthermore, compared to raw PTX, PTX-PHBV@PDA-FA NPs showed less toxicity in vivo. In conclusion, these results demonstrate the potential of PTX-PHBV@PDA-FA NPs for HCC treatment and biocompatibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biological and Chemical Engineering, Zhejiang University of Science and Technology, Hangzhou 310023, Zhejiang, China.
- Key Laboratory of Agricultural Products Chemical and Biological Processing Technology of Zhejiang Province, Hangzhou 310023, Zhejiang, China.
- College of Chemistry, Chemical Engineering and Resource Utilization, Northeast Forestry University, Harbin 150040, Heilongjiang, China.
- School of Life Sciences, Westlake Institute for Advanced Study, Westlake University, Hangzhou 310024, Zhejiang, China.
ORCID-Profile: Mingfang Wu
Förderung
- Zhejiang University of Science and Technology
Zitieren
APA
Wu, M., Wang, Q., Peng, Y., Liang, X., Lv, X., Wang, S., & Zhong, C. (2024). Enhancing Targeted Therapy in Hepatocellular Carcinoma through a pH-Responsive Delivery System: Folic Acid-Modified Polydopamine-Paclitaxel-Loaded Poly(3-hydroxybutyrate- co -3-hydroxyvalerate) Nanoparticles. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00710
Vancouver
Wu M, Wang Q, Peng Y, Liang X, Lv X, Wang S, et al. Enhancing Targeted Therapy in Hepatocellular Carcinoma through a pH-Responsive Delivery System: Folic Acid-Modified Polydopamine-Paclitaxel-Loaded Poly(3-hydroxybutyrate- co -3-hydroxyvalerate) Nanoparticles. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.3c00710
BibTeX
@article{Wu2024,
author = {Wu, Mingfang and Wang, Qi and Peng, Yaya and Liang, Xiaohui and Lv, Xiaofeng and Wang, Siying and Zhong, Chen},
title = {Enhancing Targeted Therapy in Hepatocellular Carcinoma through a pH-Responsive Delivery System: Folic Acid-Modified Polydopamine-Paclitaxel-Loaded Poly(3-hydroxybutyrate- co -3-hydroxyvalerate) Nanoparticles},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.3c00710}
}
EUVIMED